Meet Keith Heinzerling, MD, MPH:

• Prior to joining Pacific Neuroscience Institute in 2019, Keith was a physician and faculty researcher at UCLA with 20 years of experience as a clinical researcher and doing clinical trials. 
• He is a nationally recognized and published expert in Addiction Medicine and Psychedelic-Assisted Therapy. 
• As TRIP Program director from 2019 to 2025, working with Karina Sergi LMFT, Micah Linton PsyD, and Daniel Kelly MD, Dr. Heinzerling was the site Principal Investigator for clinical trials of psilocybin for major depression (Usona) and alcohol use disorder, and LSD for generalized anxiety disorder (Mindmed).
• He has guided patient treatment sessions with psilocybin and LSD and completed or supervised over 600 ketamine-assisted psychotherapy sessions with patients. 
• As the lead physician on the psychedelic therapy team, his priority is to maximize safety and minimize potential risks for patients undergoing psychedelic-assisted therapy.

Background & Education

• Dr. Heinzerling grew up in the Angeles National Forest. He graduated from Stanford University in 1992 and Stanford University School of Medicine 1998. 
• In 2020, Dr. Heinzerling completed the Certificate in Psychedelic-Assisted Therapies and Research at California Institute of Integral Studies.
• He completed his residency in Internal Medicine at NYU and Bellevue Hospital in 2002, before returning to California to study and work at UCLA where he did fellowship training, obtained his MPH in 2004, Integrated Substance Use and Addiction Programs in 2007 and was Medical Director, UCLA Center for Behavioral and Addiction Medicine from 2012-2017 and an Associate Professor, UCLA Department Family Medicine until 2019 when he joined Pacific Neuroscience Institute as Director of the TRIP Program, until Summer 2025 when he helped found PSI.

‍